Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 206
Filtrer
1.
Mucosal Immunol ; 10(4): 957-970, 2017 07.
Article de Anglais | MEDLINE | ID: mdl-27848952

RÉSUMÉ

Disruption of intestinal homeostasis can lead to inflammatory bowel diseases endowed susceptibility genes and environmental factors affecting intestinal accumulation and activation of colitogenic phagocytes. Plasmacytoid dendritic cells (pDCs) are immune cells that had been proposed to control innate and adaptive immunity through the massive secretion of type I interferon (IFN-I). However, the contribution of pDCs to the progression of intestinal inflammation remains unclear. Here we show a critical role of pDCs in the initiation of acute colonic inflammation using T-cell-independent acute colitis model with a selective ablation of pDCs. Although pDCs accumulated in the inflamed colon upon mucosal injury, deficiency of pDCs attenuated the development of acute colitis independent of IFN-I signaling, accompanied by the diminished colonic production of proinflammatory cytokines. Furthermore, deficiency of pDCs impaired the mobilization of colitogenic phagocytes into the inflamed colon possibly mediated by the abrogated mucosal production of C-C chemokine receptor 2 ligand. Thus, our findings highlight a critical role of pDCs in the induction of the colonic inflammation that regulates the colonic accumulation of inflammatory phagocytes leading to the initiation and exacerbation of acute colitis, and they may serve a key role in controlling gut mucosal immune homeostasis.


Sujet(s)
Colite/immunologie , Côlon/immunologie , Cellules dendritiques/immunologie , Inflammation/immunologie , Maladies inflammatoires intestinales/immunologie , Phagocytes/immunologie , Maladie aigüe , Animaux , Cellules cultivées , Modèles animaux de maladie humaine , Femelle , Homéostasie , Humains , Immunité muqueuse , Interféron de type I/métabolisme , Souris , Souris de lignée C57BL , Souris knockout , Récepteur à l'interféron alpha-bêta/génétique , Récepteurs CCR2/métabolisme
2.
Eur J Obstet Gynecol Reprod Biol ; 177: 48-51, 2014 Jun.
Article de Anglais | MEDLINE | ID: mdl-24793935

RÉSUMÉ

OBJECTIVE: To determine the immunological effect of dienogest (DNG), an oral anti-endometriosis drug, on peritoneal fluid (PF) macrophages collected from women with endometriosis. Although it has been suggested that DNG has direct effects on endometriotic cells, including decreased cell proliferation and decreased anti-inflammatory cytokine production, the effects of DNG on PF cells are unclear. STUDY DESIGN: The effects of DNG on PF cells from 34 women with endometriosis and 22 women without endometriosis (controls) were investigated. Expression of human leucocyte antigen (HLA)-DR in PF macrophages, obtained from the peritoneal cavity during laparoscopic surgery, was determined by flow cytometry. HLA-DR expression was measured again after PF cells had been cultured for 72 h in a humidified atmosphere at 37 °C in 5% CO2-95% air with or without DNG. After 72 h of incubation, the concentration of pro-inflammatory tumour necrosis factor (TNF)-α in the media was measured by enzyme-linked immunosorbent assay. RESULTS: HLA-DR expression was lower in PF macrophages from women with endometriosis compared with controls. However, after DNG treatment, HLA-DR expression in PF macrophages from women with endometriosis was increased to the same level as in controls. The TNF-α concentration in the media was decreased by DNG. CONCLUSIONS: DNG can restore the antigen-presenting ability of PF macrophages by increased HLA-DR expression, and may have an anti-inflammatory effect on PF macrophages in women with endometriosis.


Sujet(s)
Endométriose/immunologie , Antigènes HLA-DR/analyse , Antihormones/pharmacologie , Macrophages/effets des médicaments et des substances chimiques , Nandrolone/analogues et dérivés , Maladies du péritoine/immunologie , Facteur de nécrose tumorale alpha/métabolisme , Adulte , Liquide d'ascite/cytologie , Cellules cultivées , Femelle , Antihormones/immunologie , Humains , Macrophages/composition chimique , Macrophages/métabolisme , Nandrolone/immunologie , Nandrolone/pharmacologie
3.
Nat Nanotechnol ; 6(8): 501-5, 2011 Jul 03.
Article de Anglais | MEDLINE | ID: mdl-21725305

RÉSUMÉ

Phase-change memory technology relies on the electrical and optical properties of certain materials changing substantially when the atomic structure of the material is altered by heating or some other excitation process. For example, switching the composite Ge(2)Sb(2)Te(5) (GST) alloy from its covalently bonded amorphous phase to its resonantly bonded metastable cubic crystalline phase decreases the resistivity by three orders of magnitude, and also increases reflectivity across the visible spectrum. Moreover, phase-change memory based on GST is scalable, and is therefore a candidate to replace Flash memory for non-volatile data storage applications. The energy needed to switch between the two phases depends on the intrinsic properties of the phase-change material and the device architecture; this energy is usually supplied by laser or electrical pulses. The switching energy for GST can be reduced by limiting the movement of the atoms to a single dimension, thus substantially reducing the entropic losses associated with the phase-change process. In particular, aligning the c-axis of a hexagonal Sb(2)Te(3) layer and the 〈111〉 direction of a cubic GeTe layer in a superlattice structure creates a material in which Ge atoms can switch between octahedral sites and lower-coordination sites at the interface of the superlattice layers. Here we demonstrate GeTe/Sb(2)Te(3) interfacial phase-change memory (IPCM) data storage devices with reduced switching energies, improved write-erase cycle lifetimes and faster switching speeds.

5.
J Perinatol ; 30(2): 98-102, 2010 Feb.
Article de Anglais | MEDLINE | ID: mdl-19675574

RÉSUMÉ

BACKGROUND: The pathogenesis of thrombocytopenia during the neonatal period in Down's syndrome (DS) infants remains unclear. OBJECTIVE: To elucidate kinetic changes of serum thrombopoietin (TPO) level and platelet count, and their correlation in DS neonates. STUDY DESIGN: Twelve DS infants (male/female: 7/5, term/late preterm: 10/2) born between 1997 and 2007 were included. Blood samples were serially collected during the neonatal period and serum TPO levels were determined in 44 sera using an enzyme-linked immunosorbent assay. RESULTS: Thrombocytopenia <150 x 10(9) per liter was observed in seven (58%) patients. In 12 DS patients, the median TPO value showed 2.86 fmol ml(-1) on day 0, rose to 4.64 fmol ml(-1) on day 2, and thereafter decreased to 4.30 fmol ml(-1) on day 5, 2.40 fmol ml(-1) on days 11-15, and 1.75 fmol ml(-1) on days 28-30. This kinetics parallels that in historical non-DS controls. In 35 pair sample analysis from 11 patients without transient myeloproliferative disease, TPO level inversely correlated with platelet count (r=-0.38, P=0.023). However, there was no significant difference in TPO concentrations between thrombocytopenic and non-thrombocytopenic DS individuals. CONCLUSIONS: This is the first study to describe the relationship between TPO level and platelet count in neonates with DS. Median TPO levels and their kinetic changes in DS neonates are comparable to those in non-DS controls. In contrast to earlier findings in several studies showing higher TPO concentrations in thrombocytopenic non-DS newborns than those in non-thrombocytopenic counterparts, the response of the TPO system to thrombocytopenia in DS during the neonatal period seems suboptimal.


Sujet(s)
Syndrome de Down/sang , Thrombopénie/sang , Thrombopoïétine/sang , Études cas-témoins , Femelle , Humains , Nouveau-né , Mâle , Numération des plaquettes , Thrombopénie/physiopathologie , Thrombopoïétine/physiologie
6.
Clin Exp Immunol ; 143(3): 427-34, 2006 Mar.
Article de Anglais | MEDLINE | ID: mdl-16487241

RÉSUMÉ

To serologically determine the association of microbial superantigens and the pathogenesis of Kawasaki disease (KD), we conducted a case-control study. Serum IgG and IgM antibodies against staphylococcal enterotoxin A (SEA), SEB, SEC, toxic shock syndrome toxin-1 (TSST-1), and streptococcal pyrogenic exotoxin A (SPEA) were measured by an enzyme-linked immunosorbent assay in 293 serum samples from 65 KD patients on clinical days 1-28 and 120 control samples. The administration of immunoglobulin products, which contain high concentrations of IgG antibodies against all the superantigens, directly elevated antitoxin IgG antibodies in KD patients. In contrast, antitoxin IgM antibodies were not detected in immunoglobulin products. Actually, we found a significant elevation of IgM antibodies against SEA in KD patients in the first (median titre: 0.020, P < 0.01 versus control), second (0.024, P < 0.001), third (0.030, P < 0.001) and fourth (0.038, P < 0.001) weeks, compared to the controls (0.015). Significant differences of IgM antibodies were also true for SEB, TSST-1, and SPEA throughout the first to fourth weeks, and for SEC throughout the second to fourth weeks. The prevalence of KD patients having high IgM titres (> mean + 2SD of control values) to the 5 superantigens was increased with the clinical weeks, and reached 29-43% of KD subjects at the fourth week. This is the first study that describes kinetics of IgM antibodies against superantigens and clarifies the serological significance throughout the clinical course of KD. Our results suggest that multiple superantigens involve in the pathogenesis of KD.


Sujet(s)
Immunoglobuline M/sang , Maladie de Kawasaki/immunologie , Staphylococcus aureus/immunologie , Streptococcus pyogenes/immunologie , Superantigènes/immunologie , Anticorps antibactériens/sang , Protéines bactériennes/immunologie , Toxines bactériennes/immunologie , Études cas-témoins , Enfant , Enfant d'âge préscolaire , Entérotoxines/immunologie , Exotoxines/immunologie , Femelle , Humains , Immunoglobuline G/sang , Immunoglobulines par voie veineuse/usage thérapeutique , Nourrisson , Mâle , Protéines membranaires/immunologie , Maladie de Kawasaki/thérapie
8.
J Clin Pathol ; 57(9): 986-8, 2004 Sep.
Article de Anglais | MEDLINE | ID: mdl-15333663

RÉSUMÉ

Usually, malignant melanoma is readily diagnosed by the presence of melanin granules. Although amelanotic melanoma contains a few melanin granules, it is often difficult to differentiate from non-epithelial malignant tumours. This report describes a case of amelanotic melanoma of the vagina, which was originally suspected to be a non-epithelial malignant tumour, but was subsequently correctly diagnosed by immunohistochemical staining with the HMB-45 antibody and for the S-100 protein. A light grey tumour with superficial ulceration was located in the upper third of the vagina. The patient was treated with irradiation followed by chemotherapy. Subsequently, the tumour disappeared and cytology was negative; thus, she achieved complete remission. However, 20 months after complete remission, the tumour recurred locally: the site had a grossly black appearance, which was pathognomonic for a malignant melanoma. Thus, HMB-45 and S-100 protein immunohistochemistry confirmed the diagnosis of amelanotic melanoma.


Sujet(s)
Mélanome achromique/diagnostic , Récidive tumorale locale/diagnostic , Tumeurs du vagin/diagnostic , Antigènes néoplasiques , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Femelle , Humains , Immunohistochimie/méthodes , Mélanome/diagnostic , Mélanome achromique/traitement médicamenteux , Mélanome achromique/radiothérapie , Antigènes spécifiques du mélanome , Adulte d'âge moyen , Protéines tumorales , Protéines S100/analyse , Tumeurs du vagin/traitement médicamenteux , Tumeurs du vagin/radiothérapie
10.
Opt Express ; 11(21): 2646-53, 2003 Oct 20.
Article de Anglais | MEDLINE | ID: mdl-19471378

RÉSUMÉ

Optical-thermal and thermal-optical properties of a PdOx mask layer in a system with a superresolution near-field structure are investigated with a Z-scan technique and a heating experiment. The high photothermal stability of the PdOx mask is shown, and the reversible limit of the PdOx mask layer and a weak switch effect are revealed. The PdOx decomposition, which results in a bubble with Pd particles, is confirmed, and the laser-induced physical and chemical mechanisms in the PdOx mask layer are clarified and discussed. Our microscopic studies and heating analysis are consistent with the Z-scan results. The PdOx mask sample is also compared briefly with a PtO2 mask layer that has the same structure.

11.
Nihon Koshu Eisei Zasshi ; 48(10): 807-15, 2001 Oct.
Article de Japonais | MEDLINE | ID: mdl-11725524

RÉSUMÉ

PURPOSES: The purposes of this study are to examine two points; 1) What effects do regular visits to hospitals have on the existence of friend?. and 2) Do the elderly use hospitals as substitutes for other meeting places or independent of other places?. METHODS: Data concerning 2,447 older adults were obtained from a national survey for the elderly aged 60 and over, conducted in 1996. 1) To examine effects of regular visits to hospitals on friends, friendships as a dependent variable, regular visits to hospitals as a confounding variable, and some two way-interaction terms as independent variables were entered in logistic regression analysis. 2) To analyze relationships between hospitals and other meeting places, correspondence analyses and logistic regression were used. 3) Existence of friends whom the elderly contact at hospitals as a dependent variable, existence of friends whom they meet at other places as a confounding variable, and some two way-interaction terms as independent variables were entered in logistic regression analysis. 3) Relationships between clinics and other meeting places were also analyzed using correspondence analyses and logistic regression. RESULTS: 1. Although regular visits to hospitals did not have a significant direct impact on existence of friends, the respondents with low activities of daily living who regularly visits hospitals were more likely to have friends than ones did not visits hospitals. 2. The respondents who meet friends at hospitals were also more likely to have contacts with friends at community centers for the elderly or community organization. 3. The respondents who meet friends at clinics had similar characteristics to those who meet friends at hospitals. CONCLUSIONS: Regular visits to hospitals may contribute to maintain contacts with friends, especially in the elderly with low ADL. The elderly may use hospitals as meeting places with friends independent of other places. Hospitals may have similar functions to what clinics as meeting places with friends.


Sujet(s)
Soins ambulatoires/psychologie , Hôpitaux , Relations interpersonnelles , Socialisation , Activités de la vie quotidienne , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Japon , Modèles logistiques , Mâle , Adulte d'âge moyen
12.
J Pineal Res ; 31(3): 281-8, 2001 Oct.
Article de Anglais | MEDLINE | ID: mdl-11589764

RÉSUMÉ

We evaluated the antioxidative effect of melatonin on the oxidized low-density lipoprotein (LDL)-induced impairment of nitric oxide (NO) production in human umbilical artery, which may be the prime cause of endothelial dysfunction in pre-eclampsia. Umbilical artery sections with intact endothelium were obtained from healthy pregnant women who were delivered between 37 and 40 wk of gestation. The production of NO in the umbilical arteries was stimulated by adding L-arginine followed by incubation for 60 min. NO concentrations were estimated by measuring nitrite ions (NO(2) using high-performance liquid chromatography. LDL was oxidized by incubation with 5 microM CuSO(4) at 37 degrees C for 4 hr, followed by dialysis at 4 degrees C for 24 hr. Prior to the addition of L-arginine, the segments were treated with native or oxidized LDL (0, 50, 100, 200, 400 microg/mL), or were pre-treated with either mannitol (50 mM) or melatonin (20, 100, 500 microM) before adding oxidized LDL. Changes in L-arginine-induced NO(2)(-) production were expressed as a percentage of NO(2)(-) production at the end of pre-incubation. Treatment with oxidized LDL significantly reduced L-arginine-induced NO(2)(-) production (P<0.05), while NO(2)(-) production did not change by incubation with native LDL. Pre-treatment with melatonin significantly increased NO(2)(-) production that had been decreased by oxidized LDL (P<0.05). Similarly, pre-treatment with mannitol reversed the oxidized LDL-induced reduction in NO(2)(-) production (P<0.05). These results indicate that melatonin protects against oxidized LDL-induced inhibition of NO production in the endothelium of human umbilical arteries, most likely through its ability to scavenge hydroxyl radicals.


Sujet(s)
Antioxydants/pharmacologie , Piégeurs de radicaux libres/pharmacologie , Lipoprotéines LDL/pharmacologie , Mélatonine/pharmacologie , Monoxyde d'azote/biosynthèse , Artères ombilicales/effets des médicaments et des substances chimiques , Adulte , Arginine/pharmacologie , Chromatographie en phase liquide à haute performance , Test ELISA , Femelle , Humains , Mâle , Oxydoréduction , Grossesse , Artères ombilicales/métabolisme
13.
Circulation ; 104(15): 1773-8, 2001 Oct 09.
Article de Anglais | MEDLINE | ID: mdl-11591613

RÉSUMÉ

BACKGROUND: Estrogen increases endothelium-dependent vasodilation in postmenopausal women. However, use of progestins in combination with estrogen may counter beneficial effects of estrogen on endothelium. We investigated the effect of medroxyprogesterone acetate (MPA) on estrogen-induced increase in endothelium-dependent vasodilation in postmenopausal women. METHODS AND RESULTS: Postmenopausal women were treated daily with conjugated equine estrogen (CEE) 0.625 mg (n=14), CEE 0.625 mg and MPA 2.5 mg (n=15) or CEE 0.625 mg and MPA 5.0 mg (n=16) for 3 months. Plasma lipids and hormones were measured before and after treatment. Vasodilatory responses of the brachial artery were evaluated by measuring flow-mediated vasodilation (FMD) and nitroglycerin-induced vasodilation by use of high-resolution ultrasonography. Susceptibility of LDL to oxidation was analyzed by incubation with CuSO(4) while kinetics of conjugated diene formation was monitored. Plasma total and LDL cholesterol concentrations were decreased significantly in all groups. CEE increased FMD significantly, from 4.5+/-1.7% to 8.5+/-2.8% (P<0.001). Addition of MPA reversed this effect in a concentration-dependent manner (for MPA 2.5 mg, from 5.0+/-3.2% to 6.2+/-3.1%; for MPA 5.0 mg, from 4.9+/-3.4% to 3.6+/-3.7%; P=NS for each). No treatment significantly altered nitroglycerin-induced dilation. Lag time for conjugated diene formation was prolonged significantly in all groups, and the oxidation rate was significantly reduced. CONCLUSIONS: Concurrent MPA administration may offset favorable effects of estrogen on endothelial function in postmenopausal women. Because MPA did not diminish LDL-lowering and antioxidant effects of estrogen, MPA-induced inhibition of endothelium-dependent vasodilation may be independent of changes in oxidative susceptibility and plasma concentration of LDL.


Sujet(s)
Endothélium vasculaire/effets des médicaments et des substances chimiques , Oestrogènes conjugués (USP)/pharmacologie , Acétate de médroxyprogestérone/pharmacologie , Post-ménopause , Vasodilatation/effets des médicaments et des substances chimiques , Vitesse du flux sanguin/effets des médicaments et des substances chimiques , Pression sanguine/effets des médicaments et des substances chimiques , Artère brachiale/imagerie diagnostique , Artère brachiale/effets des médicaments et des substances chimiques , Artère brachiale/physiologie , Cholestérol/sang , Cholestérol HDL/sang , Cholestérol HDL/effets des médicaments et des substances chimiques , Cholestérol LDL/sang , Cholestérol LDL/effets des médicaments et des substances chimiques , Relation dose-effet des médicaments , Antagonisme des médicaments , Endothélium vasculaire/physiologie , Oestradiol/sang , Oestrogènes conjugués (USP)/antagonistes et inhibiteurs , Oestrone/sang , Femelle , Rythme cardiaque/effets des médicaments et des substances chimiques , Humains , Japon , Lipoprotéines LDL/sang , Lipoprotéines LDL/composition chimique , Adulte d'âge moyen , Oxydoréduction , Échographie , Degré de perméabilité vasculaire/effets des médicaments et des substances chimiques , Vasodilatation/physiologie , Vasodilatateurs/pharmacologie
15.
J Pineal Res ; 31(2): 167-72, 2001 Sep.
Article de Anglais | MEDLINE | ID: mdl-11555173

RÉSUMÉ

We investigated the effects of melatonin on ischemia/reperfusion-induced oxidative damage to mitochondria in fetal rat brain. The utero-ovarian arteries were occluded bilaterally for 20 min in female Wistar rats on day 19 of pregnancy to induce fetal ischemia. Reperfusion was achieved by releasing the occlusion and restoring circulation for 30 min. A sham operation was performed in control rats. Melatonin (10 mg/kg) or vehicle was injected intraperitoneally 60 min prior to occlusion. We measured the respiratory control index (RCI) and the adenosine 5-diphosphate (ADP)/oxygen ratio as indicators of mitochondrial respiratory activity, as well as the concentration of thiobarbituric acid-reactive substances (TBARS) in the mitochondria of fetal brain. Ischemia/reperfusion significantly elevated the concentration of TBARS and significantly reduced the RCI as well as the ADP/oxygen ratio. Melatonin treatment reversed the ischemia/reperfusion-induced reductions in the RCI (2.29 +/- 0.06-2.64 +/- 0.09, P < 0.05) and in the ADP/oxygen ratio (1.48 +/- 0.03-1.57 +/- 0.02, P < 0.05), and also reduced the elevation in concentration of TBARS (11.00 +/- 0.34-7.57 +/- 0.74 nM/mg protein, P < 0.01), resulting in values similar to those in untreated, sham-ischemic animals. The results indicate that administration of melatonin to pregnant rats may prevent ischemia/reperfusion-induced oxidative mitochondrial damage in fetal rat brain.


Sujet(s)
Lésions encéphaliques/prévention et contrôle , Encéphale/effets des médicaments et des substances chimiques , Encéphale/métabolisme , Mélatonine/pharmacologie , Lésion d'ischémie-reperfusion/prévention et contrôle , ADP/métabolisme , Animaux , Lésions encéphaliques/métabolisme , Femelle , Foetus/effets des médicaments et des substances chimiques , Foetus/métabolisme , Stress oxydatif , Consommation d'oxygène/effets des médicaments et des substances chimiques , Grossesse , Rats , Lésion d'ischémie-reperfusion/métabolisme , Substances réactives à l'acide thiobarbiturique/métabolisme
16.
J Pineal Res ; 31(2): 173-8, 2001 Sep.
Article de Anglais | MEDLINE | ID: mdl-11555174

RÉSUMÉ

We assessed the effects of melatonin, a powerful scavenger of oxygen free radicals, on ischemia/reperfusion-induced oxidative damage to mitochondria in the rat placenta. In Wistar rats at day 19 of pregnancy, feto-placental ischemia was induced by occluding both utero-ovarian arteries for 20 min. Reperfusion was achieved by releasing the occlusion and restoring circulation for 30 min. Melatonin solution or the vehicle alone was injected intraperitoneally at dose of 10 mg/kg 1 hr before occlusion. Sham-ischemic animals were treated with vehicle. Each group consisted of 10 pregnant rats. We measured placental mitochondrial respiratory control index (RCI; a marker of mitochondrial respiratory activity), the ratio of the added adenosine 5-diphosphate (ADP) concentration to consumption of oxygen during state 3 respiration (ADP/O), and the concentration of thiobarbituric acid reactive substances (TBARS) in each group. RCI and ADP/O were significantly decreased by ischemia/reperfusion, while TBARS were increased. Melatonin prevented these changes. These results indicate that exogenous melatonin protects against ischemia/reperfusion-induced oxidative damage to mitochondria in rat placenta. Melatonin could be useful in treating preeclampsia and possibly other clinical states involving excess free radical production, such as fetal growth restriction and fetal hypoxia.


Sujet(s)
Mélatonine/pharmacologie , Placenta/effets des médicaments et des substances chimiques , Placenta/traumatismes , Lésion d'ischémie-reperfusion/prévention et contrôle , ADP/métabolisme , Animaux , Femelle , Retard de croissance intra-utérin/traitement médicamenteux , Retard de croissance intra-utérin/étiologie , Retard de croissance intra-utérin/prévention et contrôle , Humains , Mitochondries/effets des médicaments et des substances chimiques , Mitochondries/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Consommation d'oxygène/effets des médicaments et des substances chimiques , Placenta/métabolisme , Pré-éclampsie/traitement médicamenteux , Pré-éclampsie/étiologie , Pré-éclampsie/prévention et contrôle , Grossesse , Rats , Rat Wistar , Lésion d'ischémie-reperfusion/métabolisme , Substances réactives à l'acide thiobarbiturique/métabolisme
17.
J Pineal Res ; 30(4): 199-205, 2001 May.
Article de Anglais | MEDLINE | ID: mdl-11339508

RÉSUMÉ

In preeclampsia, placental production of lipid peroxides is abnormally increased, while placental glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) activities are decreased. Administration of melatonin, a powerful scavenger of oxygen free radicals, also may protect the placenta from free radical-induced damage by increasing the activity of antioxidant enzymes. To test this hypothesis we administered melatonin to pregnant women before they underwent voluntary interruption of pregnancy between 7 and 9 wk of gestation. Melatonin (6 mg) was administered orally at 12:00 hr, and samples of chorion and maternal blood were obtained at the time of the procedure, 1, 2 or 3 hr later. We measured the melatonin concentration in maternal serum and activities of GSH-Px and SOD and levels of melatonin in chorionic homogenates. Melatonin administration was reflected by markedly increased melatonin concentrations in maternal serum and in chorion, with peak levels achieved 1 hr after melatonin administration (serum, 46.87 +/- 10.87 nM/L; chorionic homogenate, 4.36 +/- 1.56 pmol/mg protein). Between 1 and 3 hr after melatonin administration, GSH-Px activity in chorionic homogenates increased significantly (P < 0.001), with peak levels occurring at 3 hr (51.68 +/- 3.22 mU/mg protein per min, 137.3% of GSH-Px activity in untreated control subjects). No significant changes in chorionic SOD activity occurred during the 3-hr post-administration period. These results indicate that exogenous melatonin increases GSH-Px activity in the chorion and thereby may protect indirectly against free radical injury. Melatonin could be useful in treating preeclampsia and possibly other clinical states involving excessive free radical production, such as intrauterine fetal growth retardation and fetal hypoxia.


Sujet(s)
Chorion/effets des médicaments et des substances chimiques , Chorion/enzymologie , Glutathione peroxidase/métabolisme , Mélatonine/pharmacologie , Avortement provoqué , Activation enzymatique/effets des médicaments et des substances chimiques , Femelle , Retard de croissance intra-utérin/traitement médicamenteux , Retard de croissance intra-utérin/étiologie , Retard de croissance intra-utérin/métabolisme , Piégeurs de radicaux libres/pharmacologie , Humains , Techniques in vitro , Peroxydation lipidique/effets des médicaments et des substances chimiques , Pré-éclampsie/traitement médicamenteux , Pré-éclampsie/étiologie , Pré-éclampsie/métabolisme , Grossesse , Superoxide dismutase/métabolisme
18.
Eur J Pharmacol ; 417(1-2): 125-9, 2001 Apr 06.
Article de Anglais | MEDLINE | ID: mdl-11301067

RÉSUMÉ

We evaluated the nitric oxide (NO)-scavenging property of melatonin, demonstrated in a recent in vitro study, on vascular reactivity in the human umbilical artery. Helical sections of human umbilical artery were prepared following elective Cesarean deliveries near term. Changes in maximal tension induced by prostaglandin F(2 alpha)(5 x 10(-5) M) were measured in artery sections with an intact endothelium. Melatonin at concentrations higher than 10(-6) M increased prostaglandin F(2 alpha)-induced vascular tension. The vasospastic effect of melatonin was much less than that of L-N(G)-monomethylarginine (L-NMA, 2 x 10(-4) M), an inhibitor of NO synthesis (2.8+/-1.4%, 9.1+/-1.7%, 16.5+/-2.5%, and 29.6+/-5.9% of the L-NMA effect at melatonin concentrations of 10(-8), 10(-7), 10(-6), and 10(-5) M, respectively). Removal of the endothelium significantly reduced the vasoconstrictive effect of melatonin. Treatment with L-NMA (2 x 10(-4) M) prior to addition of prostaglandin F(2 alpha) also significantly reduced the vasoconstrictive effect of melatonin (10(-5) M). Treatments with melatonin (10(-5) M) did not affect calcium ionophore A 23187-induced relaxation or 5-hydroxytryptamine-induced constriction. The findings indicate that melatonin may potentiate vascular tension in human umbilical artery by scavenging endogenous endothelial NO, but not by inhibiting NO synthesis. However, the NO-scavenging vasoconstrictive effect of melatonin may be negligible at physiologic concentrations and very weak at pharmacologic concentrations below 10(-7) M.


Sujet(s)
Piégeurs de radicaux libres/pharmacologie , Mélatonine/pharmacologie , Artères ombilicales/effets des médicaments et des substances chimiques , Vasoconstriction/effets des médicaments et des substances chimiques , Dinoprost/pharmacologie , Relation dose-effet des médicaments , Endothélium vasculaire/physiologie , Antienzymes/pharmacologie , Femelle , Humains , Techniques in vitro , Nitric oxide synthase/antagonistes et inhibiteurs , Nitric oxide synthase/métabolisme , Artères ombilicales/physiologie , oméga-N-Méthylarginine
19.
Maturitas ; 38(2): 171-7, 2001 Apr 20.
Article de Anglais | MEDLINE | ID: mdl-11306206

RÉSUMÉ

OBJECTIVE: To investigate the effects of short-term administration of melatonin on lipoprotein metabolism in normolipidemic postmenopausal women. METHODS: Fifteen such women received 6.0 mg melatonin daily for 2 weeks. Blood was sampled before and after treatment. We measured concentrations of total cholesterol and total triglyceride in the plasma, as well as the levels of cholesterol, triglyceride, and protein in the very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). Plasma apolipoprotein levels were determined by immunoturbidimetric assay. Activities of lipoprotein lipase, hepatic triglyceride lipase, and lecithin cholesterol acyltransferase were also determined by enzymatic analysis. RESULTS: Melatonin administration significantly increased the plasma levels of triglyceride by 27.2% (P < 0.05), of VLDL-cholesterol by 37.2% (P < 0.01), of VLDL-triglyceride by 62.2% (P < 0.001), and of VLDL-protein by 30.0% (P < 0.05). However, the plasma total cholesterol level and the concentration of lipid and protein in LDL and HDL were not significantly affected. Melatonin significantly increased the plasma levels of apolipoprotein C-II by 29.5% (P < 0.005), of C-III by 17.1% (P < 0.001), and of E by 7.6% (P < 0.05). The plasma levels of apolipoprotein A-I, A-II, and B were not altered. Melatonin significantly inhibited the activity of lipoprotein lipase by -14.1% (P < 0.05), but did not significantly affect the activities of hepatic triglyceride lipase or of lecithin cholesterol acyltransferase. CONCLUSIONS: Findings indicate that melatonin increases the plasma level of VLDL particles by inhibiting the activity of lipoprotein lipase, but may not affect the plasma levels of LDL and HDL particles in postmenopausal women with normolipidemia.


Sujet(s)
Antioxydants/pharmacologie , Lipoprotéines VLDL/effets des médicaments et des substances chimiques , Mélatonine/pharmacologie , Post-ménopause , Triglycéride/métabolisme , Apolipoprotéines C/sang , Apolipoprotéines C/effets des médicaments et des substances chimiques , Cholestérol VLDL/sang , Cholestérol VLDL/effets des médicaments et des substances chimiques , Femelle , Humains , Lipoprotein lipase/sang , Lipoprotein lipase/effets des médicaments et des substances chimiques , Lipoprotéines VLDL/sang , Adulte d'âge moyen , Triglycéride/sang
20.
Obstet Gynecol ; 97(3): 333-7, 2001 Mar.
Article de Anglais | MEDLINE | ID: mdl-11239632

RÉSUMÉ

OBJECTIVE: To test whether hydrolysis of low-density lipoprotein (LDL) triglyceride by lipolytic enzymes decreases the size of LDL particles in women treated with estrogen replacement. METHODS: Fifteen postmenopausal women received 0.625 mg conjugated equine estrogens daily for 3 months. Plasma concentrations of total cholesterol, triglyceride, and high-density lipoprotein (HDL) cholesterol were measured before and after therapy. We also assayed levels of total, free, and esterified cholesterol, triglyceride, and protein in LDL. Plasma samples were incubated at 37C for 24 hours and LDL fractions were isolated by ultracentrifugation. After LDL samples were further incubated with or without lipoprotein lipase (500, 700, and 1000 ng/mL) at 37C for 24 hours, LDL triglyceride, LDL protein, and the diameter of LDL particles were measured. RESULTS: Estrogen decreased total cholesterol and increased triglyceride and HDL cholesterol in plasma. Estrogen treatment decreased the ratio of cholesteryl ester/protein, whereas the ratio of triglyceride/protein increased. Estrogen decreased LDL particle diameter. Incubation of plasma increased the ratio of LDL triglyceride/protein from 0.40 +/- 0.14 to 0.48 +/- 0.15 (P <.05) and decreased the ratio of LDL cholesteryl ester/protein from 1.17 +/- 0.25 to 1.09 +/- 0.22 (P <.05), but LDL particle diameter did not change. Incubation of LDL with lipoprotein lipase reduced the LDL triglyceride/protein ratio, and decreased the diameter of LDL particles from 25.61 +/- 0.87 nm to 24.89 +/- 0.88 nm (500 ng/mL, P <.05), 24.62 +/- 1.20 nm (700 ng/mL, P <.05), and 24.67 +/- 1.19 nm (1000 ng/mL, P <.05). CONCLUSION: In women treated with estrogen, hydrolysis of triglyceride in LDL particles might be accompanied by reduced particle size.


Sujet(s)
Cholestérol LDL/effets des médicaments et des substances chimiques , Oestrogénothérapie substitutive , Oestrogènes conjugués (USP)/pharmacologie , Lipoprotein lipase/métabolisme , Cholestérol/sang , Cholestérol HDL/sang , Cholestérol LDL/sang , Cholestérol LDL/composition chimique , Femelle , Humains , Hydrolyse , Adulte d'âge moyen , Taille de particule , Post-ménopause , Triglycéride/sang , Triglycéride/composition chimique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE